Skip to main content

Table 2 Patient presentations by group on days 8 and 15

From: Early urate-lowering therapy in gouty arthritis with acute flares: a double-blind placebo controlled clinical trial

 

Treatment group (D8) n = 20

Control group (D8) n = 20

p-valuea

Median (IQR)

Mean ± SD

Median (IQR)

Mean ± SD

Body weight (kg)

0.0(0.0 to 0.0)

0.25 ± 0.64

0.0(0.0 to 0.0)

0.28 ± 1.14

0.433

SBP (mmHg)

1.00(− 10.0 to 7.8)

0.60 ± 13.11

1.0(− 7.8 to 7.3)

2.30 ± 11.98

0.745

DBP (mmHg)

0.00(− 5.8 to 3.5)

0.40 ± 8.31

0.0(− 7.5 to 6.0)

1.80 ± 14.62

0.903

WBC (/μl)

− 960(− 2622.5 to − 55.0)

− 1392 ± 1505

− 1120(− 2642.5 to − 177.5)

− 1368.5 ± 1774.3

0.903

RBC (104/μl)

6.0(0.0–20.3)

10.30 ± 19.02

− 4.0(− 11.3 to 9.3)

− 0.25 ± 18.31

0.042*

Hb (g/dl)

0.0(− 0.1 to 0.7)

0.31 ± 0.67

− 0.1(− 0.4 to 0.4)

− 0.02 ± 0.52

0.139

Hct (%)

0.5(− 0.2 to 2.0)

0.88 ± 1.68

− 0.2(− 1.6 to 1.0)

−0.26 ± 1.78

0.047*

MCV (fl)

0.0(− 0.4 to 0.5)

0.01 ± 0.64

− 0.3(− 1.0 to 0.3)

− 0.42 ± 0.81

0.143

MCH (Pg)

0.0(− 0.4 to 0.3)

− 0.02 ± 0.44

− 0.1(− 0.5 to 0.4)

− 0.01 ± 0.46

0.968

MCHC (g/dl)

0.0(− 0.4 to 0.4)

− 0.03 ± 0.44

0.1(− 0.2 to 0.6)

0.13 ± 0.53

0.408

Platelet (/μl)

11.5 K(− 6.5 K to 27.5 K)

10750 ± 26098.7

8 K(− 6.5 K to 25.3 K)

− 900 ± 47901.1

0.787

GPT (IU/l)

0.0(− 3.8 to 7.3)

1.15 ± 7.68

4.5(− 1.8 to 26.8)

11.40 ± 18.36

0.107

Creatine (mg/dl)

0.1(0.0 to 0.2)

0.07 ± 0.12

0.02(0.0 to 0.1)

0.06 ± 0.12

0.494

CRP (mg/dl)

− 0.2(− 0.9 to 0.0)

− 0.55 ± 1.11

− 0.4(− 1 to − 0.1)

− 1.00 ± 1.96

0.336

Uric acid (mg/dl)

− 1.9(− 3.7 to 0.0)

− 1.77 ± 2.037

0.8(− 0.1 to 2.2)

1.24 ± 2.084

 < 0.001***

VAS

− 5.5(− 8.0 to − 3.0)

− 5.2 ± 3.09

− 3.5(− 5.9 to − 2.0)

− 3.63 ± 2.38

0.080

 

Treatment group (D15) n = 20

Control group (D15) n = 20

p-valuea

Median (IQR)

Mean ± SD

Median (IQR)

Mean ± SD

Body weight (kg)

0.0(0.0 to 0.0)

0.20 ± 0.70

0.0(0.0 to 0.0)

0.06 ± 0.34

0.638

SBP (mmHg)

0.5(− 6.8 to 7.8)

− 0.25 ± 9.78

2.5(− 13.3 to 5.5)

− 1.30 ± 13.09

0.892

DBP (mmHg)

− 0.5(− 6.0 to 5.3)

− 1.15 ± 11.39

0.0(− 12.3 to 5.5)

− 1.85 ± 11.53

0.946

WBC (μl)

− 1115(− 2805 to 0.0)

− 1394 ± 1820.5

− 1200(− 2682.5 to − 225.0)

− 1266.5 ± 2261.4

0.892

RBC (104/μl)

2.0(− 17.8 to 18.5)

1.45 ± 19.69

4.0(− 10.0 to 11.5)

2.20 ± 18.02

0.946

Hb (g/dl)

0.1(− 0.6 to 0.5)

0.01 ± 0.57

 0.1(− 2.0 to 0.4)

− 0.02 ± 0.52

0.870

Hct (%)

0.0(− 1.7 to 1.5)

0.05 ± 1.56

0.1(− 1.3 to 1.2)

− 0.07 ± 1.78

0.989

MCV (fl)

− 0.1(− 0.4 to 0.1)

– 0.23 ± 0.50

− 0.8(− 1.0 to 0.4)

− 0.49 ± 1.06

0.316

MCH (Pg)

− 0.1(− 0.4 to 0.3)

− 0.11 ± 0.44

–0 .1(− 0.4 to 0.1)

− 0.15 ± 045

0.786

MCHC (g/dl)

0.0(–0 .3 to 0.4)

− 0.02 ± 0.44

− 0.1(− 0.3 to 0.3)

− 0.01 ± 0.59

0.645

Platelet (μl)

8 K(− 22.3 K–27.8 K)

5050 ± 28943.6

2 K(− 8.3 K–21.5 K)

− 16800 ± 76110.4

0.579

GPT (IU/l)

0.0(− 2.0 to 4.8)

1.20 ± 5.90

7.0(− 0.8 to 15.5)

10.50 ± 17.77

0.029*

Creatine (mg/dl)

0.0(0.0 to 0.1)

0.02 ± 0.14

0.0(− 0.1 to 0.1)

0.04 ± 0.11

0.741

CRP (mg/dl)

− 0.3(− 1.1 to 0.0)

− 0.89 ± 1.53

− 0.5(− 1.4 to − 0.2)

− 01.12 ± 2.02

0.213

Uric acid (mg/dl)

− 1.7(− 2.9 to 0.0)

− 1.36 ± 1.82

0.3(− 0.2 to 1.0)

0.81 ± 2.09

0.002**

VAS

− 5.5(− 8.0 to − 3.1)

− 5.68 ± 3.01

− 4.8(− 7.0 to − 2.0)

− 4.37 ± 2.86

0.161

  1. BMI body mass index, CRP C-reactive protein, DBP diastolic blood pressure, GPT glutamic pyruvic transaminase, Hb hemoglobin, Hct hematocrit, MCH mean corpuscular hemoglobin, MCV mean corpuscular volume, RBC red blood cell, SBP systolic blood pressure, WBC white blood cell, IQR Interquartile range
  2. aMann–Whitney U test for the difference compared between the treatment group and control group
  3. *P < 0.05, **P < 0.01, ***P < 0.001